Anti- @entity7 in treatment of central XXXX .

@entity1 @entity7 @entity63 @entity2994 @entity4
Macular @entity4 along with @entity63 is responsible for decreased visual acuity in central @entity2994 . Bevacizumab (Avastin, Genentech) blocks @entity7 ( @entity7 ) induced hyperpermeability of blood vessels. In this prospective case series we investigated the efficacy of anti- @entity7 treatment in reduction of central retinal thickness (CRT) and improvement in visual acuity (VA). 25 @entity1 were followed up for 12 months and treated monthly with intravitreal bevacizumab. VA and CRT were measured at each visit. Treatment was discontinued as the peak improvement of either parameter was reached and reinstituted in case of deterioration/recurrence of @entity4 . Study endpoints included: VA using ETDRS charts, CRT and number of injections at 12 months. Mean VA from all 25 @entity1 increased by 3.1 logMAR lines (p < 0.05 compared to baseline). The improvement of VA after bevacizumab injection was in correlation with a decrease in CRT In subgroup analyses, @entity1 receiving bevacizumab injection within the first 3 months after CRVO showed an average VA gain of 4.2 logMAR lines. Mean of 4.5 injections was needed to control the disease during the follow-up period. Bevacizumab treatment was effective in VA and reducing CRT. It appears from subgroup analysis that initiation of treatment early in the course of disease produced better functional outcome. Several injections were needed to control the disease. Regular OCT examinations and retreatment are advised in order to maintain initially reached VA.
